| Literature DB >> 29211216 |
Felipe Homem Valle1, Fernando Pivatto Júnior2, Bruna Sessim Gomes1, Tanara Martins de Freitas1, Vanessa Giaretta1, Miguel Gus1.
Abstract
INTRODUCTION: The outcomes of Jehovah's Witness (JW) patients submitted to open heart surgery may vary across countries and communities. The aim of this study was to describe the morbidity and mortality of JW patients undergoing cardiac surgery in a tertiary hospital center in Southern Brazil.Entities:
Mesh:
Year: 2017 PMID: 29211216 PMCID: PMC5701095 DOI: 10.21470/1678-9741-2017-0012
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Demographic characteristics of the sample.
| Variable | JW (n=16) | Non-JW (n=48) | |
|---|---|---|---|
| Age | 60.6±12.1 | 63.3±11.1 | 0.416 |
| Male sex | 9 (56.3) | 32 (66.7) | 0.652 |
| Systemic hypertension | 14 (87.5) | 41 (85.4) | 1.0 |
| Previous smoking | 6 (37.5) | 29 (60.4) | 0.192 |
| Current smoking (< 30 days) | __ | 5 (10.4) | 0.319 |
| Chronic pulmonary disease | __ | 1 (2.1) | 1.0 |
| Pulmonary hypertension (≥ 31 mmHg) | 5 (31.2) | 13 (27.1) | 0.756 |
| Previous MI | 5 (31.3) | 15 (31.3) | 1.0 |
| Recent MI | 1 (6.3) | 10 (20.8) | 0.265 |
| Diabetes | 4 (25.0) | 17 (35.4) | 0.645 |
| Diabetes on insulin | __ | 4 (8.3) | 0.564 |
| NYHA class III/IV heart failure | 3 (18.7) | 9 (18.8) | 1.0 |
| LVEF | 56.0 (37.5-67.0) | 55.5 (42.2-68.7) | 0.951 |
| CCS class 4 angina | 1 (6.3) | 8 (16.7) | 0.430 |
| Unstable angina | __ | 1 (2.1) | 1.0 |
| Previous heart surgery | 1 (6.3) | 2 (4.2) | 1.0 |
| Atrial fibrillation | 1 (6.3) | 6 (12.5) | 0.669 |
| Extracardiac arteriopathy | 1 (6.3) | 6 (12.5) | 0.669 |
| Active endocarditis | 1 (6.3) | __ | 0.250 |
| Creatinine clearance (mL/min) | 88.6 (50.4-102.3) | 72.2 (55.1-98.9) | 0.617 |
| Preoperative hemodialysis | 1 (6.3) | __ | 0.250 |
| Acetylsalicylic acid use | 6 (37.5) | 28 (58.3) | 0.247 |
| Erythropoietin use | 1 (6.7) | __ | 0.238 |
| Hematocrit (%) | 39.7 (35.2-42.6) | 37.4 (33.1-41.7) | 0.438 |
| Hemoglobin (g/dL) | 13.6 (11.7-14.2) | 12.7 (11.1-14.2) | 0.571 |
| EuroSCORE II | 1.29 (0.66-3.08) | 1.43 (0.72-2.63) | 0.988 |
CCS=Canadian Cardiovascular Society; JW=Jehovah's Witness; LVEF=left ventricular ejection fraction; MI=myocardial infarction; NYHA=New York Heart Association
Excluding a chronic kidney disease on hemodialysis patient.
Data presented as number (%), mean ± standard deviation or median (interquartile range).
Surgical data.
| Variable | JW | Non-JW | |
|---|---|---|---|
| Non-elective surgery | 1 (6.3) | 4 (8.3) | 1.0 |
| Surgery | |||
| Isolated CABG | 7 (43.8) | 28 (58.3) | 0.469 |
| Isolated biological AVR | 3 (18.8) | 6 (12.5) | |
| Isolated biological MVR | 2 (12.5) | 1 (2.1) | |
| CABG + biological AVR | 1 (6.3) | 1 (2.1) | |
| CABG + biological aortic valved graft | 1 (6.3) | __ | |
| Isolated mechanical AVR | 1 (6.3) | 3 (6.3) | |
| Mechanical AVR + MVR | 1 (6.3) | __ | |
| Isolated mechanical MVR | __ | 2 (4.2) | |
| Mechanical aortic valved graft + aneurysmectomy | __ | 1 (2.1) | |
| CABG + aorta pseudoaneurysm correction | __ | 1 (2.1) | |
| Mechanical aortic valved graft | __ | 1 (2.1) | |
| Biological aortic valved graft | __ | 1 (2.1) | |
| Heart tumor removal | __ | 1 (2.1) | |
| Interventricular communication correction | __ | 1 (2.1) | |
| Resection of subaortic membrane + septoplasty | __ | 1 (2.1) | |
| Extracorporeal circulation time (minutes) | 58.5 (50.7-71.5) | 67.5 (55.2-90.0) | 0.139 |
| Cross-clamp time (minutes) | 38.5 (31.2-51.0) | 48.0 (40.0-65.0) | 0.054 |
AVR=aortic valve replacement; CABG=coronary artery bypass graft surgery; JW=Jehovah's Witness; MVR=mitral valve replacement
Data presented as number (%) or median (interquartile range).
Hospital outcomes.
| Outcome | JW | Non-JW | |
|---|---|---|---|
| Mortality | 3 (18.8) | 2 (4.2) | 0.095 |
| Morbidity | 4 (25.0) | 14 (29.2) | 1.0 |
| Last hematocrit (%) | 28.6 (23.6-33.6) | 28.8 (26.5-32.9) | 0.625 |
| Last hemoglobin (g/dL) | 9.2 (7.5-11.6) | 9.4 (8.8-10.9) | 0.593 |
| Length of stay (days) | 6.5 (6.0-9.5) | 7.0 (7.0-9.7) | 0.143 |
JW=Jehovah's Witness. Data presented as number (%) or median (interquartile range).
Fig. 1Comparison of the predicted and observed hospital mortality in JW and non-JW patients accordingly EuroSCORE II.
Hospital morbidity.
| Hospital morbidity | JW | Non-JW | |
|---|---|---|---|
| Mechanical ventilation > 48h | 4 (25.0) | 4 (8.3) | 0.099 |
| Need for hemodialysis | 3 (20.0) | 1 (2.1) | 0.039 |
| Reintubation | 3 (18.8) | 3 (6.3) | 0.159 |
| Antibiotic use[ | 2 (13.3) | 10 (20.8) | 0.714 |
| Creatinine > 2 mg/dL | 1 (6.7) | 4 (8.3) | 1.0 |
| Perioperative MI | 1 (6.3) | 2 (4.2) | 1.0 |
| Need for IABP | 1 (6.3) | __ | 0.250 |
| Reintervention for bleeding | 1 (6.3) | 3 (6.3) | 1.0 |
| Stroke | __ | 2 (4.2) | 1.0 |
JW=Jehovah's Witness; IABP=intra-aortic balloon pump; MI=myocardial infarction
Excluding a chronic kidney disease on hemodialysis patient.
Excluding an active endocarditis patient.
Data presented as number (%).
Comparison of current study with previous retrospective comparative studies.
| Variable | Valle et al. (current study) | Marinakis et al.[ | Stamou et al.[ | Bhaskar et al.[ | Pattakos et al.[ |
|---|---|---|---|---|---|
| n | 16 | 31 | 49 | 49 | 322 |
| Age | 60.6±12.1 | 62±15 | 62.7±9.5 | 65.3±10.1 | 62±13 |
| Isolated CABG | 7 (43.8) | 15 (48.4) | 38 (77.5) | 25 (51.0) | 209 (64.9) |
| Hospital mortality | 3 (18.8) | 1 (3.2) | 3 (6.1) | 1 (2.0) | 10 (3.1) |
CABG=coronary artery bypass graft surgery
Data presented as number (%) or mean ± standard deviation.
| Abbreviations, acronyms & symbols | |
|---|---|
| JW | = Jehovah's Witness |
| HCPA | = Hospital de Clínicas de Porto Alegre |
| SPSS | = Statistical Package for Social Sciences |
| VAP | = Ventilator-associated pneumonia |
| Authors' roles & responsibilities | |
|---|---|
| FHV | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| FPJ | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| BSG | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| TMF | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| VG | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| MG | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |